PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) CEO Outlines Next Steps for Promising New Technologies
Company is targeting $3.8 trillion preventative medicine industry Sol-gel delivery system administers CBD-based medicines directly to the brain via nasal passages Company R&D includes anti-diabetes and obesity gene therapy and powerful non-addictive painkiller Health sciences company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) expects to make promising progress in the research and development of a number of exciting products in 2018, according to the company’s chairman, CEO and President Stephen Van Deventer in an audio interview (http://cnw.fm/7CrAF). He explained that, while pharmaceutical and nutraceutical companies are well-established, there is a relatively untapped $3.8 trillion a year industry in preventative…